CD19 and B-cell chronic lymphocytic leukemia: This approach improved the overall quality of CD19 CAR T cells generated from CLL patients, in that the ibrutinib-treated CAR T cells expressed lower percentages of exhaustion markers including PD-1, TIM-3 and LAG-3, and had elevated TNFα and IFNγ production following target stimulation in vitro (58).